Day: October 30, 2024

Raanana, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) — Polyrizon Ltd. (the “Company” or “PLRZ”), a development stage biotech company specializing in the development of innovative medical device hydrogels, today announced the closing of its underwritten initial public offering of 958,903 units at a combined public offering price of $4.38 per unit, with each unit each consisting of one ordinary share and three warrants to purchase one ordinary share per warrant, with an initial exercise price of $4.38 per share. Aggregate gross proceeds were $4.2 million, prior to deducting underwriting discounts and offering expenses. In addition, PLRZ has granted Aegis Capital Corp. (“Aegis”) a 45-day option to purchase up to 143,835 additional units, equal to 15% of the number of ordinary shares sold in the offering solely to...

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) — Mercer International Inc. (Nasdaq: MERC) (the “Company”) today announced that it has completed its previously announced private offering of $200.0 million aggregate principal amount of 12.875% senior notes due October 1, 2028 (the “Additional Notes”). The Additional Notes were issued at a price of 103.000% of their principal amount, plus accrued interest from October 1, 2024, for a yield to worst of 11.624%. The Additional Notes were issued as additional notes under the indenture dated September 21, 2023, pursuant to which the Company previously issued $200.0 million aggregate principal of 12.875% senior notes due 2028. The net proceeds of the offering, along with cash on hand, will be used by the Company to redeem $300.0 million in principal amount of its currently...

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) — Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the closing of its initial public offering of 1,300,000 ordinary shares at a public offering price of US$4.00 per share. The ordinary shares commenced trading on the Nasdaq Global Market on October 29, 2024 under the symbol “GELS.” The gross proceeds from the offering, before deducting underwriting fees and other offering expenses payable by the Company, were US$5.2 million. The Company intends to use the net proceeds from the offering for various purposes, including funding certain manufacturing, marketing and research and development activities.   The Benchmark Company, LLC acted as the lead managing...

TOKYO, Oct. 30, 2024 (GLOBE NEWSWIRE) — Lead Real Estate Co., Ltd. (Nasdaq: LRE) (“LRE” or “the Company”), a Japanese real estate developer of luxury residential properties including single-family homes and condominiums across Tokyo, Kanagawa prefecture and Sapporo, today announced its participation in the Radio NIKKEI IR Seminar in Sapporo on Saturday, October 26, 2024. Eiji Nagahara, CEO, was the lead presenter. The event is part of the Radio NIKKEI Japan Tour IR and Eimei Sakurai Stocks Lecture 2024-2025 nationwide series. As part of its ongoing Investor Relations activities, Lead Real Estate saw this as an opportunity to increase its presence among Japanese retail investors through this event. According to the World Bank, Japan ranks third globally in terms of total savings per household. Also, regulators modified the Nippon...

LONDON, Oct. 30, 2024 (GLOBE NEWSWIRE) — Navigator Holdings Ltd. (described herein as “Navigator Gas” or the “Company”) (NYSE: NVGS), the owner and operator of the world’s largest fleet of handysize liquefied gas carriers, announces today that it will release its results for the three months ended September 30, 2024, after markets close in New York, on Wednesday, November 6, 2024. The next day, Thursday, November 7, 2024, at 10:00 A.M. E.T., the Company’s management team will host a Zoom conference call and slide presentation to discuss the financial results. Zoom Conference Call DetailsParticipants should register for the conference call and slide presentation through the following link: https://us06web.zoom.us/webinar/register/WN_7duVkhhCQ6iIpvX3q4pRywOr join by phone:United States: +1 929 436 2866United Kingdom: +44...

Geneva, Switzerland, Oct. 30, 2024 (GLOBE NEWSWIRE) — SEALSQ Organizes “The Day After Tomorrow: IoT Security in the Post-Quantum Age” Webinar Webinar starts at 11:00 am ET (4:00 pm CET) Join the webinar via https://hubs.li/Q02VFxJg0 SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today is hosting a webinar titled “The Day After Tomorrow: IoT Security in the Post-Quantum Age.” This event will showcase SEALSQ’s latest advancements in post-quantum technologies and address critical questions from clients and industry leaders about the future of security in the quantum era. Webinar Focus: The Impact of Quantum Computing on CybersecurityThe event...

Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, Oct. 30, 2024 (GLOBE NEWSWIRE) — (TSX: PIC.PR.A) – Premium Income Corporation (the “Fund”) is pleased to announce a successful overnight treasury offering of 4,350,000 Preferred Shares. Gross proceeds of the offering are expected to be $65,250,000. The offering is expected to close on or about November 6, 2024, and is subject to certain closing conditions including approval by the Toronto Stock Exchange (“TSX”). The Preferred Shares will be offered at a price of $15.00 per Preferred Share representing a yield on the original issue price of 8.50%. The trading price on the TSX for the Preferred Shares as at the last trade on October 29, 2024, was $15.16. Since the inception of the Fund, the aggregate dividends declared on the Preferred...

Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation Data from ARTACUS clinical trial of RP1 monotherapy in solid organ transplant patients with advanced cutaneous malignancies selected for encore poster presentation WOBURN, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that a late-breaking abstract featuring the IGNYTE clinical trial primary analysis has been selected for oral presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) being held November 6-10, 2024, in Houston, Texas. Data from the ARTACUS clinical trial of RP1 monotherapy in solid organ transplant...